DATE: June 20, 2018
TIME: 07:00AM PDT, 10:00AM EDT

Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes and cost. One of the major hurdles to effective sepsis management is the limitations of conventional diagnostics, which are blood-culture based and take 1 to 5 or more days to identify sepsis-causing pathogens. Blood culture also misses 35-50% of infections altogether on first blood draw and can be greatly affected by the presence of antimicrobials. These delays impact patient outcomes as one hour of delayed treatment increases mortality risk by nearly 8%.

To advance sepsis care, hospitals are turning to new technology that does not rely on blood culture. This year, six new peer reviewed studies have been published on T2Dx diagnostics, which provide blood culture independent sepsis pathogen ID results in 3 to 5 hours. Due to improved detection, these studies from the U.S. and EU demonstrate that clinicians can achieve faster targeted therapy, better outcomes, enhanced stewardship, and reduced cost of care. The T2Dx Instrument runs the first FDA-cleared tests to identify deadly sepsis-causing pathogens in whole blood: the T2Candida Panel and the now FDA-Cleared T2Bacteria Panel.

In this webinar you will:

• Review the latest clinical data on the accuracy and impact of blood culture independent diagnostics
• Demonstrate the potential for new diagnostics to improve outcomes for patients suspected of sepsis while improving stewardship
• Understand opportunities and barriers to implementation of blood culture independent diagnostics into routine clinical care and sepsis management protocols